liso-cel
liso-cel: sourced relationships with 1 company · 2 clinical trials tracked.
liso-cel evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could liso-cel → JUNO affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Juno Therapeutics, Inc. (JUNO) Relapsed or Refractory Follicular Lymphoma | Phase 3 |
Clinical Trial Registry Records (2)
The CAROLYN Trial: Lisocabtagene Maraleucel as First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients
Primary endpoint: Progression-free Survival (PFS)
A Global Randomized Multicenter Phase 3 Trial to Compare the Efficacy and Safety of Lisocabtagene Maraleucel (JCAR017/BMS-986387) to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma (TRANSFORM FL)
Primary endpoint: Progression-free survival (PFS)
Frequently asked questions
Which companies have sourced relationships with liso-cel?
liso-cel has dated SEC/FDA relationship records for Juno Therapeutics, Inc..
How many clinical trials involve liso-cel?
BioSniper tracks 2 clinical trials involving liso-cel.